Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01038804 · ClinicalTrials.gov registry record · Phase 2
A Study of YM155 Plus Docetaxel as First-Line Treatment in Subjects With HER2 Negative Metastatic Breast Cancer
A Phase 2 study, sponsored by Astellas Pharma.
- Completed
- Registry status
- Phase 2
- Development phase
- 101
- Enrollment target
NCT01038804: Completed Phase 2 study, sponsored by Astellas Pharma.
NCT01038804 is a Phase 2 study that has completed, run by Astellas Pharma. The registered enrollment target is 101 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (24% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01038804, a Phase 2 study, has completed, sponsored by Astellas Pharma.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 101 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate survival, response rate, safety and tolerability of YM155 given in combination with docetaxel as first-line treatment in subjects with human epidermal growth factor 2 non-overexpressing (HER2 negative) metastatic breast cancer.
Interventions
- DRUG Docetaxel
- DRUG YM155
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 101 participants |
| Start Date | 2009-12 |
| Est. Completion | 2013-06 |
| Phase | Phase 2 |
What the finished NCT01038804 record still lists
NCT01038804 is an interventional study that assigns participants to a tested intervention. The registered 101 participants enrollment target is mid-sized for trials with a published cap, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (24% lower).
The record links to 0 conditions, and to 2 interventions - of which Docetaxel is the first listed.
NCT01038804 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01038804 about?
NCT01038804 is a clinical study titled "A Study of YM155 Plus Docetaxel as First-Line Treatment in Subjects With HER2 Negative Metastatic Breast Cancer". The purpose of this study is to evaluate survival, response rate, safety and tolerability of YM155 given in combination with docetaxel as first-line treatment in subjects with human epidermal growth factor 2 non-overexpressing (HER2 negative) metastatic breast cancer.
What is the current status of trial NCT01038804?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 101 participants. The study started on 2009-12. Estimated completion is 2013-06.
What interventions are being tested in trial NCT01038804?
The interventions under investigation include: Docetaxel (DRUG), YM155 (DRUG).
Who is sponsoring clinical trial NCT01038804?
This trial is sponsored by Astellas Pharma, which has 165 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01038804's enrollment target sits among peer trials
101 672nd of 2000 higher than 1,329 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04033497 · 101 participants · NA
Treatment Response Assessment Maps to Delineate Necrosis From Tumor After Stereotactic Radiation in Brain Metastases
- NCT05111574 · 101 participants · Phase 2
Using Nivolumab Alone or With Cabozantinib to Prevent Mucosal Melanoma Return After Surgery
- NCT05984680 · 101 participants
COPD Care Pathway Among Patients With Cancer
- NCT06266299 · 101 participants · Phase 1
A Study of KK2269 in Adult Participants With Solid Tumors
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia